Correvio Pharma Corp. (CORV) Analysts See $-0.22 EPS

July 14, 2018 - By Frank Plummer

Analysts expect Correvio Pharma Corp. (NASDAQ:CORV) to report $-0.22 EPS on August, 14.They anticipate $0.04 EPS change or 15.38 % from last quarter’s $-0.26 EPS. After having $-0.24 EPS previously, Correvio Pharma Corp.’s analysts see -8.33 % EPS growth. The stock decreased 0.26% or $0.01 during the last trading session, reaching $3.91. About 36,471 shares traded. Correvio Pharma Corp. (NASDAQ:CORV) has 0.00% since July 14, 2017 and is . It has underperformed by 12.57% the S&P500.

Correvio Pharma Corp., a specialty pharmaceutical company, provides various products to meet the needs of acute care physicians and patients worldwide. The company has market cap of $136.71 million. It develops, acquires, and commercializes various brands for the in-hospital acute care market segment. It currently has negative earnings. The company's portfolio of marketed brands include Xydalba for the treatment of acute bacterial skin and skin structure infections; Zevtera/Mabelio (ceftobiprole medocaril sodium), a cephalosporin antibiotic for the treatment of community and hospital-acquired pneumonia; and Brinavess (vernakalant IV) for the rapid conversion of recent onset atrial fibrillation to sinus rhythm.

More news for Correvio Pharma Corp. (NASDAQ:CORV) were recently published by: Investingnews.com, which released: “Pharmaceutical Update: Q2 2018 in Review” on July 10, 2018. Streetinsider.com‘s article titled: “Correvio Pharma (CORV) Reports At The Market Offering” and published on July 10, 2018 is yet another important article.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.





Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: